Overview

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125134 and its active metabolite CORT125201 after single and multiple ascending oral doses of CORT125134 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Corcept Therapeutics
Treatments:
Cortisone
Cortisone acetate
Mifepristone
Prednisone